Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Myra L. Patchen"'
Autor:
Koshu Okubo, Michael D. Brenner, Xavier Cullere, Gurpanna Saggu, Myra L. Patchen, Nandita Bose, Saki Mihori, Zhou Yuan, Clifford A. Lowell, Cheng Zhu, Tanya N. Mayadas
Publikováno v:
Cell Reports, Vol 35, Iss 7, Pp 109142- (2021)
Summary: The interaction of the human FcγRIIA with immune complexes (ICs) promotes neutrophil activation and thus must be tightly controlled to avoid damage to healthy tissue. Here, we demonstrate that a fungal-derived soluble β-1,3/1,6-glucan bind
Externí odkaz:
https://doaj.org/article/9a4ac42e04014a60b236ae9a01a774d1
Autor:
Walburga Engel-Riedel, Jamie Lowe, Paulette Mattson, J. Richard Trout, Richard D. Huhn, Michele Gargano, Myra L. Patchen, Richard Walsh, My My Trinh, Mariève Dupuis, Folker Schneller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract Background BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncology antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and sa
Externí odkaz:
https://doaj.org/article/a97a56be9beb405a92afcd70845c53f1
Autor:
Myra L. Patchen
Publikováno v:
Radioprotectors ISBN: 9781003068181
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0665fb31dce28bc2f84012d5fc9c9876
https://doi.org/10.4324/9781003068181-13
https://doi.org/10.4324/9781003068181-13
Autor:
J.F. Marier, Janet B Bautista, Myra L. Patchen, Michele Gargano, Richard Walsh, Paulo S Tioleco, Myra L Flores, Gerardo H Cornelio, Maria E Tamayo, Martin Beliveau, Michael R Kurman
Publikováno v:
Colorectal Cancer. 5:95-108
Aim: Investigate the safety, pharmacokinetics (PK) and efficacy of BTH1677/cetuximab, with and without irinotecan, in patients with metastatic colorectal cancer (mCRC). Patients & methods: Patients with recurrent or progressive mCRC were assigned to
Autor:
Nandita Bose, Gurpanna Saggu, Myra L. Patchen, Saki Mihori, Cheng Zhu, Zhou Yuan, Xavier Cullere, Clifford A. Lowell, Tanya N. Mayadas, Michael D. Brenner, Koshu Okubo
Publikováno v:
Cell reports
Cell reports, vol 35, iss 7
Cell Reports, Vol 35, Iss 7, Pp 109142-(2021)
Cell reports, vol 35, iss 7
Cell Reports, Vol 35, Iss 7, Pp 109142-(2021)
SUMMARY The interaction of the human FcγRIIA with immune complexes (ICs) promotes neutrophil activation and thus must be tightly controlled to avoid damage to healthy tissue. Here, we demonstrate that a fungal-derived soluble β-1,3/1,6-glucan binds
Publikováno v:
Clinical Colorectal Cancer. 15:222-227
Background Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes/macrophages to exert antitumor activity against complement opsonized tumor cells. In
Publikováno v:
Investigational New Drugs
SummaryBackground BTH1677 is a beta glucan pathogen associated molecular pattern (PAMP) currently being investigated as a novel cancer therapy. Here, the initial safety and pharmacokinetic (PK) results of BTH1677 in healthy subjects are reported. Sub
Autor:
J. R. Trout, Myra L. Patchen, P. Sadjadian, Folker Schneller, Nandita Bose, P. Mattson, M. Gargano, Jens Kollmeier, Jamie Lowe, M. Beliveau, Richard Walsh, J. F. Marier, Michael Thomas, Keith B. Gorden
Publikováno v:
Investigational New Drugs
SummaryIntroduction BTH1677, a 1,3–1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety
Autor:
Ben J. Harrison, Nandita Bose, Xiaohong Qiu, Kyle S. Michel, Jeremy R. Graff, Richard Walsh, Mariana I. Nelson, Nadine R. Ottoson, Adria Jonas, Keith B. Gorden, Steven M. Leonardo, Michael E. Danielson, Kathleen E. Ertelt, Peter Maimonis, Anissa S.H. Chan, Myra L. Patchen
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 11, p e0165909 (2016)
PLoS ONE, Vol 11, Iss 11, p e0165909 (2016)
Imprime PGG (Imprime), an intravenously-administered, soluble β-glucan, has shown compelling efficacy in multiple phase 2 clinical trials with tumor targeting or anti-angiogenic antibodies. Mechanistically, Imprime acts as pathogen-associated molecu
Autor:
Mark T. Uhlik, Michael E. Danielson, Nadine R. Ottoson, Nandita Bose, Jamie Lowe, Jeremy R. Graff, Richard D. Huhn, Ben Harrison, Xiaohong Qiu, Steven M. Leonardo, Jose Iglesias, Myra L. Patchen, Anissa S.H. Chan, Kyle S. Michel, M. Ma, Keith B. Gorden, Richard Walsh, Katie Ertelt, A. Bykowski Jonas
Publikováno v:
European Journal of Cancer. 69:S106-S107